UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

LRRK2 Levels and Phosphorylation in Parkinson's Disease Brain and Cases With Restricted Lewy Bodies

Dzamko, N; Gysbers, AM; Bandopadhyay, R; Bolliger, MF; Uchino, A; Zhao, Y; Takao, M; ... Halliday, GM; + view all (2016) LRRK2 Levels and Phosphorylation in Parkinson's Disease Brain and Cases With Restricted Lewy Bodies. Movement Disorders , 32 (3) pp. 423-432. 10.1002/mds.26892.

[thumbnail of Dzamko_et_al-2017-Movement_Disorders (1).pdf] Text
Dzamko_et_al-2017-Movement_Disorders (1).pdf - Published Version
Access restricted to UCL open access staff

Download (1MB)

Abstract

Background: Leucine rich repeat kinase 2 (LRRK2) is a promising target for the treatment of Parkinson's disease; however, little is known about the expression of LRRK2 in human brain and if/how LRRK2 protein levels are altered in Parkinson's disease. Objectives: We measured the protein levels of LRRK2 as well as its phosphorylation on serines 910, 935, and 973 in the postmortem brain tissue of Parkinson's disease patients and aged controls with and without Lewy bodies. Methods: LRRK2 and its phosphorylation were measured by immunoblot in brain regions differentially affected in Parkinson's disease (n = 30) as well as subjects with Lewy bodies restricted to the periphery and lower brain stem (n = 25) and matched controls without pathology (n = 25). Results: LRRK2 levels were increased in cases with restricted Lewy bodies, with a 30% increase measured in the substantia nigra. In clinical Parkinson's disease, levels of LRRK2 negatively correlated to disease duration and were comparable with controls. LRRK2 phosphorylation, however, particularly at serine 935, was reduced with clinical Parkinson's disease with a 36% reduction measured in the substantia nigra. Conclusions: Our data show that LRRK2 phosphorylation is reduced with clinical PD, whereas LRRK2 expression is increased in early potential prodromal stages. These results contribute to a better understanding of the role of LRRK2 in idiopathic Parkinson's disease and may aid efforts aimed at therapeutically targeting the LRRK2 protein. © 2016 International Parkinson and Movement Disorder Society

Type: Article
Title: LRRK2 Levels and Phosphorylation in Parkinson's Disease Brain and Cases With Restricted Lewy Bodies
DOI: 10.1002/mds.26892
Publisher version: https://doi.org/10.1002/mds.26892
Language: English
Additional information: This version is the version of record. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: Science & Technology, Life Sciences & Biomedicine, Clinical Neurology, Neurosciences & Neurology, brain, alpha-synuclein, Parkinson's disease, Lewy body, phosphorylation, RICH REPEAT KINASE-2, 14-3-3 BINDING, CYTOPLASMIC LOCALIZATION, ALPHA-SYNUCLEIN, MUTATIONS, EXPRESSION, DEPHOSPHORYLATION, ASSOCIATION, INHIBITION, INCREASES
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Clinical and Movement Neurosciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases
URI: https://discovery.ucl.ac.uk/id/eprint/10048721
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item